New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Details

Serval ID
serval:BIB_8EEEF1A119B7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
Journal
Journal of Immunology
Author(s)
Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., Lienard D., Guillaume P., Krieg A.M., Cerottini J.C., Romero P., Leyvraz S., Rufer N., Speiser D.E.
ISSN
0022-1767 (Print)
ISSN-L
0022-1767
Publication state
Published
Issued date
2006
Peer-reviewed
Oui
Volume
177
Number
3
Pages
1670-1678
Language
english
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Abstract
Although increasing evidence suggests that CTL are important to fight the development of some cancers, the frequency of detectable tumor-specific T cells is low in cancer patients, and these cells have generally poor functional capacities, compared with virus-specific CD8(+) T cells. The generation with a vaccine of potent CTL responses against tumor Ags therefore remains a major challenge. In the present study, ex vivo analyses of Melan-A-specific CD8(+) T cells following vaccination with Melan-A peptide and CpG oligodeoxynucleotides revealed the successful induction in the circulation of effective melanoma-specific T cells, i.e., with phenotypic and functional characteristics similar to those of CTL specific for immunodominant viral Ags. Nonetheless, the eventual impact on tumor development in vaccinated melanoma donors remained limited. The comprehensive study of vaccinated patient metastasis shows that vaccine-driven tumor-infiltrating lymphocytes, although activated, still differed in functional capacities compared with blood counterparts. This coincided with a significant increase of FoxP3(+) regulatory T cell activity within the tumor. The consistent induction of effective tumor-specific CD8(+) T cells in the circulation with a vaccine represents a major achievement; however, clinical benefit may not be achieved unless the tumor environment can be altered to enable CD8(+) T cell efficacy.
Keywords
Adult, Aged, Antigens, Neoplasm, CD8-Positive T-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/pathology, Cancer Vaccines/administration & dosage, Cancer Vaccines/immunology, Cell Movement/immunology, Clone Cells, CpG Islands/immunology, Cytomegalovirus/immunology, Epitopes, T-Lymphocyte/immunology, Herpesvirus 4, Human/immunology, Humans, Immunophenotyping, Lymphocyte Activation/immunology, Lymphocyte Count, Lymphocytes, Tumor-Infiltrating/immunology, Lymphocytes, Tumor-Infiltrating/pathology, MART-1 Antigen, Melanoma/immunology, Melanoma/pathology, Neoplasm Proteins/immunology, Oligodeoxyribonucleotides/administration & dosage, Oligodeoxyribonucleotides/immunology, T-Lymphocytes, Regulatory/immunology, T-Lymphocytes, Regulatory/pathology, Tumor Cells, Cultured, Vaccines, Subunit/administration & dosage, Vaccines, Subunit/immunology
Pubmed
Web of science
Create date
28/01/2008 11:14
Last modification date
20/08/2019 14:52
Usage data